Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.600
-0.040 (-2.44%)
Nov 21, 2024, 4:00 PM EST - Market closed
Chemomab Therapeutics Analyst Ratings
Total Analysts
3
Consensus Rating
Strong Buy
Price Target
$7.33
Upside
+358.13%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $13 → $11 | Buy | Reiterates | $13 → $11 | +587.50% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +150.00% | May 13, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +275.00% | May 6, 2024 |
| Oppenheimer | Oppenheimer | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 8, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +337.50% | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +337.50% | Oct 6, 2023 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +337.50% | Apr 18, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $20 | Buy | Maintains | $30 → $20 | +1,150.00% | Mar 10, 2022 |
| Aegis Capital | Aegis Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +1,775.00% | Dec 7, 2021 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $45 | Buy | Initiates | $45 | +2,712.50% | May 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $42 | Buy | Initiates | $42 | +2,525.00% | May 7, 2021 |